Around 80% of lung cancers are non-small-cell lung cancers (NSCLC), whose management remains challenging despite recent advances based on tumor genetic stratification using relevant biomarkers, such as EGFR, ALK, ROS-1, MET and KRAS2. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.